Primary Job Title Member of the Board of Directors Primary Organization 
Nektar Therapeutics
Gender Male
Roy Whitfield has served as our director since August 2000.
Roy Whitfield is the former Chairman of the Board and Chief Executive Officer of Incyte Corporation, a drug discovery and development company he co-founded in 1991.
From January 1993 to November 2001, Roy Whitfield served as its Chief Executive Officer and from November 2001 until
June 2003 as its Chairman.
From 1984 to 1989, Roy Whitfield held senior operating and business development positions with Technicon Instruments Corporation, a medical instrumentation company, and its predecessor company, Cooper Biomedical, Inc., a biotechnology and medical diagnostics company.
Prior to his work at Technicon, Roy Whitfield spent seven years with the Boston Consulting Group's international consulting practice.
He currently serves as a director of Incyte Corporation, Illumina, Inc., a developer, manufacturer and marketer of integrated systems for analysis of genetic variations and biological functions, and Station X, Inc., a private development stage company.
Since February 2008, he has also served as Executive Chairman of the board of directors of Bioseek.
Roy Whitfield received a B.S. in mathematics from Oxford University and an M.B.A. from Stanford University.
